Erdheim-Chester disease – A case report
Abstract
Introduction. Erdheim-Chester disease (ECD) is a rare non-Langerhans-cell histiocytosis. About 500 cases are published so far. It is multisystemic disease characterised by bilateral symmetric long bones sclerosis. Main histopathological finding is accumulation of big foamy histiocytes, immunohistochemically positive to CD68, and negative to S-100 and CD1a. There are no guidelines that reliably identify population that requires therapy, but symptomatic ECD, organ failure and central nervous system involvement require treatment. Case report. We described a patient with a multisystemic form of ECD affecting long bones, the hypophysis, abdomen, and the peripheral nerves. Five years after initial symptoms ECD was suspected. Prednison was initiated, 60 mg once a day. After obtaining the diagnosis of ECD, interferon alpha 2A was introduced, but soon after stopped due to severe side effects. Considering that histiocytes were positive to platelet derived growth factor receptor alpha (PDGFR alpha) imatinib mesylate was started, but after two months stopped due to no clinical and radiological improvement. The disease was worsening and the patient died. Conclusion. We described the patient with intraperitoneal form of ECD, without cardiac and pulmonary involvement. There are several important issues: the diagnosis of ECD could be difficult to make, three treatment regimens were included and the patient died nine years after the initial symptoms due to indolent course of the disease and unsuccessful treatment.
References
Chester W. Über lipoid Granulomatose. Virchows Arch Pathol Anat 1930; 279(2): 561–602.
Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: The paradigm of erdheim-chester disease. Front Immunol. 2014; 5: 281.
Emile J, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Char-lotte F, Hyman DM, et al. Recurrent RAS and PIK3CA muta-tions in Erdheim-Chester disease. Blood 2014; 124(19): 3016−9.
Bosco J, Allende A, Varikatt W, Lee R, Stewart GJ. Does the BRAF(V600E) mutation herald a new treatment era for Erd-heim-Chester disease? A case-based review of a rare and diffi-cult to diagnose disorder. Intern Med J 2015; 45(3): 348−51.
Antunes C, Graça B, Donato P. Thoracic, abdominal and muscu-loskeletal involvement in Erdheim-Chester disease: CT, MR and PET imaging findings. Insights Imaging 2014; 5(4): 473−82.
Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, Wechsler J, Brun B, Remy M, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore) 1996; 75(3): 157−69.
Bourke SC, Nicholson AG, Gibson GJ. Erdheim-Chester disease: Pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax 2003; 58(11): 1004−5.
Yano S, Kobayashi K, Kato K, Tokuda Y, Ikeda T, Takeyama H. A case of Erdheim-Chester disease effectively treated by cyclo-phosphamide and prednisolone. Nihon Kokyuki Gakkai Zas-shi 2007; 45(1): 43−8.
Ho P, Smith C. High-dose methotrexate for the treatment of relapsed central nervous system erdheim-chester disease. Case Rep Hematol 2014; 2014: 269359.
Darstein F, Kirschey S, Heckl S, Rahman F, Schwarting A, Schuch-mann M, et al. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J 2014; 44(1): 90−2.
Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, et al. Treatment of Erdheim-Chester disease with cladribine: A rational approach. Br J Ophthalmol 2004; 88(6): 844−7.
Adam Z, Sprláková A, Rehák Z, Koukalová R, Szturz P, Krejcí M, et al. Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide. Klin Onkol 2011; 24(5): 367−81.(Czeck)
Broccoli A, Stefoni V, Faccioli L, Agostinelli C, Spinardi L, Pastore TM, et al. Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: A case report and a review of literature. Rheumatol Int 2012; 32(7): 2209−13.
Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: Results in eight patients. Arthritis Rheum 2006; 54(10): 3330−6.
Ota M, Sakamoto M, Sato K, Yoshida Y, Funakubo AY, Akiyama Y, et al. Immunopathological analysis of Erdheim-Chester dis-ease with massive ascites. Intern Med 2012; 51(19): 2825−30.
Gupta A, Aman K, Al-Babtain M, Al-Wazzan H, Morouf R. Mul-tisystem Erdheim-Chester disease; a unique presentation with liver and axial skeletal involvement. Br J Haematol 2007; 138(3): 280.
Pan A, Doyle T, Schlup M, Lubcke R, Schultz M. Unusual manife-station of Erdheim-Chester disease. BMC Gastroenterol 2011; 11: 77.
Gundling F, Nerlich A, Heitland W, Schepp W. Biliary manifesta-tion of Erdheim-Chester disease mimicking Klatskin's carci-noma. Am J Gastroenterol 2007; 102(2): 452−4.
Ivan D, Neto A, Lemos L, Gupta A. Erdheim-Chester disease: A unique presentation with liver involvement and vertebral os-teolytic lesions. Arch Pathol Lab Med 2003; 127(8): e337−9.
Tevlin R, Cahalane AM, Larkin JO, Treacy A, Connaghan D, Winter DC. Gastrointestinal Erdheim-Chester disease. Ir Med J 2014; 107(5): 149−50.
Vermeiren P, Van Laecke S, Cuvelier C, De Loose D, Vanholder R. Progressive dysphagia caused by Erdheim-Chester disease. QJM 2014; 107(12): 1015–7.
Ben-Yaakov G, Munteanu D, Sztarkier I, Fich A, Schwartz D. Erd-heim Chester: A rare disease with unique endoscopic features. World J Gastroenterol 2014; 20(25): 8309−11.
Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, et al: Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: result in eight patient. Arthritis Rheum 2006; 54(10): 3330–6.
Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111(11): 5413−5.
Boissel N, Wechsler B, Leblond V. Treatment of refractory Erd-heim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001; 135(9): 844−5.
Srikulmontree T, Massey DH, Roberts NW. Treatment of skeletal Erdheim-Chester disease with zoledronic acid: Case report and proposed mechanisms of action. Rheumatol Int 2007; 27(3): 303−7.
Aouba A, Georgin-Lavialle S, Pagnoux C, Martin SN, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116(20): 4070−6.
Miller RC, Villà S, Kamer S, Pasquier D, Poortmans P, Micke O, et al. Palliative treatment of Erdheim-Chester disease with radio-therapy: A Rare Cancer Network study. Radiother Oncol 2006; 80(3): 323−6.
Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, et al. Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial. Blood 2015; 126(10): 1163−71.
Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, et al. Tumor necrosis factor α as a master regulator of in-flammation in Erdheim-Chester disease: Rationale for the treatment of patients with infliximab. J Clin Oncol 2012; 30(28): e286−90.
Tzoulis C, Schwarzlmüller T, Gjerde IO, Søfteland E, Neckelmann G, Biermann M, et al. Excellent response of intramedullary Erd-heim-Chester disease to vemurafenib: A case report. BMC Res Notes 2015, 8: 171.
Tran T, Pariente D, Guitton C, Delwail A, Barat-Houari M, Meinzer U. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology (Oxford) 2014; 53(12): 2312−4.
Cives M, Simone V, Rizzo FM, Dicuonzo F, Cristallo Lacalamita M, Ingravallo G, et al. Erdheim-Chester disease: A systematic re-view. Crit Rev Oncol Hematol 2015; 95(1): 1−11.